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Abstract
Background:  Two recombinant, live attenuated human parainfluenza virus type 1 (rHPIV1)
mutant viruses have been developed, using a reverse genetics system, for evaluation as potential
intranasal vaccine candidates. These rHPIV1 vaccine candidates have two non-temperature
sensitive (non-ts) attenuating (att) mutations primarily in the P/C gene, namely CR84GHNT553A (two
point mutations used together as a set) and CΔ170 (a short deletion mutation), and two ts att
mutations in the L gene, namely LY942A (a point mutation), and LΔ1710–11 (a short deletion), the last
of which has not been previously described. The latter three mutations were specifically designed
for increased genetic and phenotypic stability. These mutations were evaluated on the HPIV1
backbone, both individually and in combination, for attenuation, immunogenicity, and protective
efficacy in African green monkeys (AGMs).
Results: The rHPIV1 mutant bearing the novel LΔ1710–11 mutation was highly ts and attenuated in
AGMs and was immunogenic and efficacious against HPIV1 wt challenge. The rHPIV1-CR84G/
Δ170HNT553ALY942A and rHPIV1-CR84G/Δ170HNT553ALΔ1710–11 vaccine candidates were highly ts, with
shut-off temperatures of 38°C and 35°C, respectively, and were highly attenuated in AGMs.
Immunization with rHPIV1-CR84G/Δ170HNT553ALY942A protected against HPIV1 wt challenge in both
the upper and lower respiratory tracts. In contrast, rHPIV1-CR84G/Δ170HNT553ALΔ1710–11 was not
protective in AGMs due to over-attenuation, but it is expected to replicate more efficiently and be
more immunogenic in the natural human host.
Conclusion:  The rHPIV1-CR84G/Δ170HNT553ALY942A  and rHPIV1-CR84G/Δ170HNT553ALΔ1710–11
vaccine candidates are clearly highly attenuated in AGMs and clinical trials are planned to address
safety and immunogenicity in humans.
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Background
Human parainfluenza virus type 1 (HPIV1) is responsible
for approximately 6% of pediatric hospitalizations due to
respiratory tract disease with significant illness occurring
predominantly in infants and young children [1]. Clinical
manifestations range from mild disease, including rhini-
tis, pharyngitis, and otitis media, to more severe disease,
including croup, bronchiolitis, and pneumonia [1-6].
Collectively, human parainfluenza virus serotypes 1, 2
and 3 (HPIV1, 2 and 3) are the second leading causative
agents of pediatric hospitalizations due to respiratory dis-
ease following respiratory syncytial virus (RSV) [7,1].
However, a licensed vaccine is currently not available for
the prevention of illness caused by any HPIV.
HPIV1 is an enveloped, non-segmented, single-stranded,
negative-sense RNA virus belonging to the family Para-
myxoviridae, genus Respirovirus, of which HPIV3 is also a
member. The HPIV1 genome is 15,600 nucleotides in
length and contains six genes in the order 3'-N-P/C-M-F-
HN-L-5', which encode three nucleocapsid-associated
proteins including the nucleocapsid protein (N), the
phosphoprotein (P), and the large polymerase protein (L)
and three envelope-associated proteins including the
internal matrix protein (M) and the fusion (F) and hemag-
glutinin-neuraminidase (HN) transmembrane surface
glycoproteins [8]. F and HN are the two viral neutraliza-
tion antigens and are major viral protective antigens. The
P/C gene of HPIV1 contains a second open reading frame
(ORF) that encodes up to four accessory C proteins, C', C,
Y1 and Y2, that initiate at four separate translational start
codons in the C ORF and are carboxy co-terminal [1].
However, it is unclear whether the Y2 protein is actually
expressed during HPIV1 infection [9]. The HPIV1 C pro-
teins have recently been shown to act as antagonists of the
innate immune response during virus infection by inhib-
iting type 1 interferon (IFN) production and signaling of
IFN through its receptor [10].
Our laboratory is developing a live attenuated virus vac-
cine for HPIV1 for intranasal administration to infants
and young children. The intranasal route of administra-
tion is needle-free and has the advantage of direct stimu-
lation of local immunity as well as induction of a
substantial systemic immune response [11]. Furthermore,
compared to an inactivated vaccine, a live virus vaccine
stimulates a broader spectrum of innate and adaptive
immune responses [11]. The recent licensure of the triva-
lent live attenuated influenza virus vaccine (Flumist™)
indicates that it is possible to achieve an acceptable bal-
ance between attenuation and immunogenicity with a live
attenuated respiratory virus vaccine [12].
Reverse genetics provides a method for introducing atten-
uating mutations in desired combinations into wild type
(wt) HPIV1 [13-16]. Temperature sensitive (ts) attenuat-
ing (att) and non-ts att mutations have been developed
that, in combination, can enhance both the phenotypic
and genetic stability of a HPIV1 vaccine candidate. The
licensed cold-adapted influenza A viruses contain similar
non-ts and ts att mutations [17,18]. In the case of HPIV1,
non-ts att mutations have been introduced into the P/C
gene that inactivate the anti-IFN activities of the C acces-
sory proteins [10]. One of these mutations (CΔ170) is a
deletion mutation that affects codon 170 of the HPIV1 C
protein; deletion mutations are desirable because they are
essentially free of same-site reversion and thus provide for
enhanced genetic and phenotypic stability. The CΔ170
mutation inhibited both the production of Type 1 IFN
and the signaling of IFN through its receptor and specified
an att phenotype in hamsters and African green monkeys
(AGMs) [10,16]. A second non-ts att mutation involves a
pair of amino acid substitutions, CR84G and HNT553A, that
attenuates HPIV1 for AGMs when they are present
together but not individually. This attenuating pair of
mutations was not further genetically stabilized, i.e., it is
possible to revert to a wt phenotype with a single nucleo-
tide substitution at either mutation. A substitution at
amino acid position 942 of L, LY942A, generated a ts att
mutation that was engineered for increased genetic and
phenotypic stability by the strategy of identifying a codon
whose amino acid assignment yielded a ts att phenotype
and which would require three nucleotide substitutions
for reversion [13]. A virus bearing this stabilized mutation
was attenuated in both AGMs and hamsters [15].
The present study consists of two parts. First, we devel-
oped an additional ts att mutation involving a small dele-
tion in the HPIV1 L protein. This mutation was originally
identified as a ts att point mutation in the bovine PIV3
(BPIV3) L protein (LS1711I) [19]. The corresponding site in
the HPIV1 L protein was identified as position 1710 by
sequence alignment, and this codon and its downstream
neighbor (codon 1711) were deleted to yield the LΔ1710–11
mutation. This gave us two genetically stabilized ts att
mutations in L, the LΔ1710–11 and the LY942A mutations. In
the second part of the study, the two non-ts att mutations
in C, namely the CR84G/HNT553A set and the CΔ170 muta-
tion, were combined with each other and with either the
LΔ1710–11 mutation or the LY942A mutation to develop two
live intranasal HPIV1 vaccine candidates. Each of these
vaccine candidates contained at least one genetically sta-
bilized ts and non-ts att mutation. These viruses were eval-
uated for their in vitro attenuation phenotype and for
replication, efficacy and immunogenicity in AGMs.
Results
Construction and recovery of mutant rHPIV1 viruses
Point and deletion mutations in the P/C, HN and L genes
that attenuate HPIV1 for replication in the respiratoryVirology Journal 2007, 4:67 http://www.virologyj.com/content/4/1/67
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tract of hamsters or AGMs are indicated in Table 1[13-16].
The CR84G mutation is a single nucleotide substitution
mutation that affects both the P and C proteins and that
results in amino acid substitutions of R84 to G in C, and
E87 to G in P (Table 1) [15]. The CR84G mutation is atten-
uating in the upper respiratory tract (URT) of AGMs, but
only in the presence of the HNT553A point mutation indi-
cated in Table 1[15]. The CR84G and HNT553A mutations are
each based on single nucleotide substitutions (Table 1),
and thus the att phenotype would be lost by reversion at
either position. The CΔ170 deletion mutation in HPIV1
involves a six-nucleotide deletion, a length that was cho-
sen to comply with the "rule of six" [20]. This deletion
results in a loss of two amino acids and substitution of a
third at codon positions 168–170 in C (RDF to S), and a
deletion of amino acids GF in P at codon positions 172–
173 (Table 1) [16]. The changes in the C protein also
would be present in the nested C', Y1, and Y2 proteins
(not shown) [16]. The Y942A mutation in L has three
nucleotide changes in codon 942 and specifies a geneti-
cally and phenotypically stabilized ts att phenotype [13].
In the present study, the LΔ1710–11 deletion mutation in
HPIV1 was created at a site that corresponds by sequence
alignment to a ts att point mutation originally identified
in BPIV3 [19]. Importation of this BPIV3 point mutation
has previously been shown to attenuate HPIV2 [21]. Here,
the LΔ1710–11 mutation contains a six-nucleotide deletion
that results in a deletion of amino acids AE at codon posi-
tions 1710–11 of the L gene of HPIV1 (Table 1).
The mutations in Table 1 were introduced into the HPIV1
antigenomic cDNA individually or in combinations to
yield the panel of rHPIV1 viruses listed in Table 2. These
viruses were recovered following transfection of cDNAs
into HEp-2, BHK-T7 or Vero cells and biologically cloned
in LLC-MK2 cells, and each was sequenced in its entirety
to confirm the presence of the engineered mutation(s)
and the absence of adventitious mutations. Unexpectedly,
we were unable to isolate rHPIV1 containing the LΔ1710–11
mutation by itself and without adventitious mutations
despite four attempts to do this using multiple replicates
each time. However, we were able to recover virus bearing
LΔ1710–11 in the presence of CR84G without adventitious
mutations. Thus, our analysis of the phenotype of the
LΔ1710–11 mutation was performed in the presence of the
CR84G mutation, which is neither ts nor att [15].
Characterization of rHPIV1s containing single att 
mutations
We first sought to characterize the rHPIV1 mutants bear-
ing the four single att mutations (the CR84GHNT553A set,
CΔ170, LY942A, and LΔ1710–11) to define the contributions of
the individual mutations to the phenotypes of the rHPIV1
mutants (Groups 3, 4, 5, 7 in Tables 2 and 3). We previ-
ously generated and evaluated the rHPIV1-CR84GHNT553A
and rHPIV1-CΔ170 viruses (each containing a single non-ts
att mutation) in vitro and in vivo [13,15,16]. These previ-
ously evaluated single-mutation viruses were included
here for the purpose of comparison with viruses contain-
ing the other individual mutations as well as combina-
tions of mutations. An rHPIV1 mutant, rHPIV1-LY942A,
bearing the Y942A mutation in L was generated for the
present study. We had previously generated and character-
ized a virus, rHPIV1-CR84GHNT553ALY942A, containing the
LY942A mutation in combination with the CR84GHNT553A
pair of mutations [13]. The newly generated rHPIV1-
LY942A virus would permit evaluation of its specific contri-
bution to the level of temperature sensitivity in vitro and
attenuation in vivo. The rHPIV1 mutant bearing the indi-
vidual att mutation LΔ1710–11 (rHPIV1-CR84GLΔ1710–11) also
Table 1: Summary of the mutations introduced into the rHPIV1 genomea.
Gene Mutationb ORF nt changes wt → mutant c Type of 
mutation
Codon 
position
Amino acid change # nt changes for 
reversion to wt
P/C R84G C AGA → GGA point 84 R → G1
PG AG → GGG point 87 E → G1
Δ170d CA G G GAT TTC → AGC deletion 168–170 RDF → S (D deletion; 3 nt 
deletions in the flanking R-F 
codons results in a S 
substitution)
6 (insertions)d
P GGA TTT→ deletion deletion 172–173 GF deletion 6 (insertions)
HN T553A HN ACC → GCC point 553 T → A1
L Y942Ae L TAT→ GCG point 942 Y → A3 e
Δ1710–11d L GCT GAG→ deletion deletion 1710–11 AE deletion 6 (insertions)d
a HPIV1 strain Washington/1964, GenBank accession no. NC_003461.
b The nomenclature used to describe each mutation indicates the wt amino acid, the codon position and the new amino acid, or the position of the 
deletion (Δ), with respect to the C, HN or L protein.
c The nucleotides (nt) affected by substitution or deletion are shown underlined and in bold type.
d Designed for increased genetic stability by use of a deletion. Deletions involved six nt to conform to the rule of six [20].
e Designed for increased genetic stability by the use of a codon that differs by three nucleotides from codons yielding a wild type assignment.Virology Journal 2007, 4:67 http://www.virologyj.com/content/4/1/67
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contained the CR84G mutation, although this latter muta-
tion is phenotypically silent on its own, as already noted.
The level of temperature sensitivity of replication of the
four viruses with single att mutations was first studied
(Table 2, groups 3, 4, 5, and 7) and compared to that of
rHPIV1 wt and rHPIV1-CR84G. Viruses containing only P/
C gene mutations with or without the HN mutation were
non-ts, whereas each of the L gene mutations specified a ts
phenotype in vitro. The single LY942A mutation specified a
shut-off temperature of 37°C, a level of temperature sen-
sitivity that was equivalent to that previously observed for
rHPIV1-CR84GHNT553ALY942A (Table 2, compare Groups 5
and 6). These data indicate that the LY942A mutation is
responsible for the observed ts  phenotype of rHPIV1-
CR84GHNT553ALY942A  (Table 2). The LΔ1710–11  mutation
specified an even stronger ts phenotype than the LY942A
mutation (Table 2). The LΔ1710–11 mutation clearly con-
tributes significantly to the ts  property of rHPIV1-
CR84GLΔ1710–11 since rHPIV1-CR84G was confirmed to be
non-ts  (Table 2, compare Groups 2 and 7). Therefore,
both LY942A and LΔ1710–11 are ts mutations in HPIV1. In a
multiple cycle growth curve, the two newly generated
rHPIV1 mutants with single att mutations, rHPIV1-LY942A
and rHPIV1-CR84GLΔ1710–11, reached a titer equivalent to
that of rHPIV1 wt in both LLC-MK2 and Vero cells (Figure
1). Thus, these individual mutations do not significantly
restrict replication in vitro at the permissive temperature
of 32°C and therefore could be useful mutations in vac-
cine candidates.
The level of replication of rHPIV1-LY942A and rHPIV1-
CR84GLΔ1710–11 in AGMs was next evaluated and compared
to that of rHPIV1 wt and the other two single att mutants
(Table 3, Groups 1, 3, 4, 5, 7). A rHPIV1 mutant was con-
sidered attenuated if it exhibited a significant (P < 0.05)
reduction in replication in either the mean peak virus titer
or the mean sum of the daily virus titers (a measure of the
total amount of virus shed over the duration of the infec-
tion) in either the nasopharyngeal (NP) swab (represent-
ative of the upper respiratory tract, URT) or tracheal lavage
(TL) samples (representative of the lower respiratory tract,
LRT) compared to the HPIV1 wt group. We have previ-
ously demonstrated that rHPIV1-CR84G replicates to levels
equivalent to HPIV1 wt in AGMs, whereas rHPIV1-
CR84GHNT553A  and rHPIV1-CR84GHNT553ALY942A  were
attenuated in AGMs [15,16]. Here, both rHPIV1-LY942A
and rHPIV1-CR84GLΔ1710–11 were significantly attenuated
in the URT and LRT of AGMs in comparison to HPIV1 wt.
The levels of attenuation of rHPIV1-LY942A and rHPIV1-
CR84GHNT553ALY942A were comparable, indicating that the
LY942A mutation is an attenuating mutation by itself and
that the attenuation specified by the LY942A mutation is not
additive to that specified by the CR84GHNT553A att muta-
tion. The rHPIV1-CR84GLΔ1710–11 mutant also was signifi-
cantly attenuated in AGMs, reducing virus titer in
Table 2: Level of temperature sensitivity of replication of rHPIV1 mutants in vitro.
Mean reduction (log10) in virus titer ± S.E. at the indicated 
temperature compared to 32°C c
Virus a Virus titer ± 
S.E. at 32°C b
35°C 36°C 37°C 38°C 39°C 40°C Shut-off (°C) d
1 HPIV1 wt 7.7 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.2 ± 0.1 0.7 ± 0.1 1.3 ± 0.1 3.0 ± 0.3 -
2e rHPIV1-CR84G 9.2 ± 0.4 0.4 ± 0.2 0.4 ± 0.6 0.8 ± 0.5 0.3 ± 0.4 1.8 ± 0.6 4.5 ± 0.9 -
3e rHPIV1-CR84GHNT553A 7.8 ± 0.1 -0.3 ± 0.2 -0.3 ± 0.2 -0.2 ± 0.2 0.1 ± 0.2 0.7 ± 0.2 2.5 ± 0.6 -
4e rHPIV1-CΔ170 7.9 ± 0.3 0.2 ± 0.2 0.7 ± 0.8 0.5 ± 0.2 1.0 ± 0.3 2.6 ± 0.7 4.5 ± 1.0 -
5r H P I V 1 - L Y942A 8.0 ± 0.1 0.2 ± 0.3 1.2 ± 0.3 2.6 ± 1.1c,d 6.4 ± 0.4 ≥6.8 f ≥6.8 37°C
6e rHPIV1-CR84GHNT553ALY942A 7.4 ± 0.2 0.4 ± 0.4 0.5 ± 0.4 2.3 ± 0.4 4.0 ± 0.6 6.0 ± 0.4 ≥6.4 37°C
7r H P I V 1 - C R84GLΔ1710–11 7.5 ± 0.7 0.8 ± 0.7 3.0 ± 0.6 4.8 ± 0.2 ≥6.3 ≥6.3 ≥6.3 36°C
8r H P I V 1 - C R84G/
Δ170HNT553ALY942A
6.3 ± 0.1 0.3 ± 0.2 0.9 ± 0.6 2.0 ± 0.3 4.9 ± 0.2 ≥5.1 ≥5.1 38°C
9r H P I V 1 - C R84G/
Δ170HNT553ALΔ1710–11
6.4 ± 0.3 2.6 ± 0.6 4.0 ± 0.4 ≥5.2 ≥5.2 ≥5.2 ≥5.2 35°C
a Data are the mean of three to sixteen experiments.
b Viruses were titrated on LLC-MK2 cells at either permissive (32°C) or potentially restrictive (35°C – 40°C) temperatures for 7 days and virus 
titers are expressed as the mean ± standard error (S.E.). The limit of detection was 1.2 log10 TCID50/ml.
c Values in bold indicate restricted replication, where the mean log10 reduction in virus titer at the indicated temperature vs 32°C was 2.0 log10 or 
greater than the difference in titer of HPIV1 wt at the same temperature vs 32°C. A virus is designated ts if restricted replication at 35°C–40°C is 
observed.
d Underlined values indicate viral shut-off temperature, the lowest temperature at which restricted replication is observed.
e These data have been previously published [13] [15] [16] and are included here for the purposes of comparison.
f The symbol "≥" indicates that virus titers were at the limit of detection and therefore the reduction in virus titer versus 32°C is greater than or 
equal to the indicated value. There is no S.E. value for viruses at the limit of detection.Virology Journal 2007, 4:67 http://www.virologyj.com/content/4/1/67
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comparison to HPIV1 wt by 2.7 and 3.0 log10 50%-tissue-
culture-infectious-doses (TCID50)/ml in the URT and LRT,
respectively (Table 3). Since rHPIV1-CR84G was confirmed
not to be attenuated in AGMs (Table 3, Group 2) [16], this
suggests that the LΔ1710–11 mutation contributes signifi-
cantly to the observed attenuation phenotype.
The immunogenicity and protective efficacy resulting
from immunization with rHPIV1s containing single att
mutations were evaluated in AGMs by measuring post-
immunization HPIV1 hemagglutination inhibiting (HAI)
serum antibody titers and by challenging immunized and
control animals with HPIV1 wt 28 days following immu-
nization and determining challenge virus titers in the URT
and LRT (Table 4). AGMs immunized with rHPIV1s con-
taining single att mutations (Groups 3, 4, 5, and 7) devel-
oped post-immunization HAI serum antibodies and
manifested resistance to replication of the challenge virus.
The rHPIV1-CR84GLΔ1710–11  mutant, which showed a
strong level of attenuation following immunization of
AGMs, was protective only at a low level in the URT.
Combination of three single att mutations into rHPIV1 to 
generate two live attenuated HPIV1 vaccine candidates
Having identified the in vitro and in vivo properties of the
four single att mutations, we used this information to gen-
erate two live attenuated HPIV1 vaccine candidates con-
taining both non-ts and ts attenuating mutations. These
vaccine candidates were designed to incorporate a back-
bone containing one stabilized non-ts attenuating muta-
tion, CΔ170, as well as the CR84GHNT553A att mutation. The
addition of this second mutation (the CR84GHNT553A att
mutation) would be expected to increase the overall sta-
bility of the virus by increasing the total number of atten-
uating mutations present in the vaccine candidate. To
generate the two live attenuated HPIV1 vaccine candi-
dates, either the stabilized ts att LY942A mutation or the
LΔ1710–11 deletion mutation was added to the rHPIV1-
CR84G/Δ170HNT553A  backbone. We then evaluated the
resulting combination mutants, rHPIV1-CR84G/
Δ170HNT553ALY942A  and rHPIV1-CR84G/Δ170HNT553ALΔ1710–
11, as potential vaccine candidates.
These two viruses were first evaluated for their level of
temperature sensitivity of replication in vitro (Table 2).
The level of temperature sensitivity of rHPIV1-CR84G/
Δ170HNT553ALY942A and rHPIV1-CR84G/Δ170HNT553ALΔ1710–11
(Groups 8 and 9 in Table 2) was equivalent to that of the
corresponding L gene single-mutation viruses from which
they were derived (namely rHPIV1-LY942A and rHPIV1-
CR84GLΔ1710–1, Groups 5 and 7 in Table 2). This indicates
that combining the non-ts and ts mutations in rHPIV1-
CR84G/Δ170HNT553ALY942A  and rHPIV1-CR84G/
Δ170HNT553ALΔ1710–11 did not significantly alter their over-
Table 3: Level of replication of HPIV1 vaccine candidates in the upper and lower respiratory tract of African green monkeys.
Mean peak virus titer 
(log10 TCID50/ml)c
Mean sum of the daily virus 
titers (log10 TCID50/ml)d
atte
Virusa Shut-off 
temperature b
No. of 
animals
NP swabf TL g NP swabf TL g URT LRT
1 HPIV1 wt - 14 4.2 ± 0.2 3.9 ± 0.3 26.4 ± 1.5 12.2 ± 1.6 - -
2h rHPIV1-CR84G - 4 3.6 ± 0.4 4.0 ± 0.5 21.0 ± 1.7 11.7 ± 2.5 No No
3h rHPIV1-CR84GHNT553A - 12 2.1 ± 0.2i 4.8 ± 0.3 10.5 ± 0.9 14.3 ± 1.1 Yes No
4h rHPIV1-CΔ170 - 6 3.4 ± 0.5 2.3 ± 0.5 14.8 ± 1.9 5.1 ± 0.8 Yes Yes
5r H P I V 1 - L Y942A 37°C 4 2.3 ± 0.1 2.3 ± 0.2 16.9 ± 0.7 8.4 ± 1.2 Yes Yes
6h rHPIV1-CR84GHNT553ALY942A 37°C 8 2.4 ± 0.2 2.1 ± 0.3 12.9 ± 1.0 5.1 ± 0.6 Yes Yes
7r H P I V 1 - C R84GLΔ1710–11 36°C 4 1.5 ± 0.4 0.9 ± 0.2 8.6 ± 1.8 3.2 ± 0.6 Yes Yes
8r H P I V 1 - C R84G/Δ170HNT553ALY942A 38°C 4 1.2 ± 0.3 0.6 ± 0.1 5.9 ± 0.5 2.6 ± 0.1 Yes Yes
9r H P I V 1 - C R84G/Δ170HNT553ALΔ1710–11 35°C 4 0.9 ± 0.3 ≤0.5 ± 0.0 6.3 ± 0.5 ≤2.5 ± 0.0 Yes Yes
a Monkeys were inoculated i.n. and i.t. with 106 TCID50 of the indicated virus in a 1 ml inoculum at each site. Data are representative of one to five 
experiments.
b Shut-off temperature is defined in footnote d, Table 2.
c Virus titrations were performed on LLC-MK2 cells at 32°C and expressed as the mean ± S.E of the individual peak virus titers for the animals in 
each group irrespective of day. The limit of detection was 0.5 log10 TCID50/ml.
d Mean sum of the daily virus titers: the sum of the titers for all of the days of sampling was determined for each animal individually, and the mean 
was calculated for each group. On days when virus was not detected, a value of was 0.5 log10 TCID50/ml was assigned for the purpose of calculation. 
The mean sum of the lower limit of detection was 5.0 log10 TCID50/ml for NP swabs and 2.5 log10 TCID50/ml for TL samples.
e Virus is designated att in the URT or LRT based on a significant reduction in either mean peak titer or mean sum of daily titers compared to the 
HPIV1 wt group (see footnote h).
f Nasopharyngeal (NP) swab samples were collected on days 1–10 post-infection.
g Tracheal lavage (TL) samples were collected on days 2, 4, 6, 8, and 10 post-infection.
h These data have been previously published [13] [15] [16] and are included here for the purposes of comparison.
i Underlined values indicate a statistically significant reduction compared to corresponding HPIV1 wt titer, P < 0.05 (Student-Newman-Keuls multiple 
comparison test).Virology Journal 2007, 4:67 http://www.virologyj.com/content/4/1/67
Page 6 of 13
(page number not for citation purposes)
all level of temperature sensitivity of replication in vitro.
A multiple cycle growth curve at 32°C demonstrated that
each virus achieved titers in Vero cells that will allow effi-
cient manufacture. Specifically, the rHPIV1-CR84G/
Δ170HNT553ALY942A and rHPIV1-CR84G/Δ170HNT553ALΔ1710–11
vaccine candidates reached peak titers of 7.9 and 7.2 log10
TCID50/ml, respectively, in Vero cells (Figure 1).
The level of replication of rHPIV1-CR84G/
Δ170HNT553ALY942A and rHPIV1-CR84G/Δ170HNT553ALΔ1710–11
Comparison of the replication of HPIV1 wt and rHPIV1 mutant viruses containing the indicated mutations in the P/C, HN and  L genes in a multiple cycle growth curve Figure 1
Comparison of the replication of HPIV1 wt and rHPIV1 mutant viruses containing the indicated mutations in 
the P/C, HN and L genes in a multiple cycle growth curve. Monolayer cultures of LLC-MK2 cells and Vero cells were 
infected at a multiplicity of infection of 0.01 TCID50/cell and incubated at 32°C. The medium was removed on days 0 (residual 
inoculum), 2 and 4–11 post-infection, frozen for later determination of virus titers, and replaced by fresh medium containing 
trypsin. The virus titers shown are the means of 3 replicate cultures.Virology Journal 2007, 4:67 http://www.virologyj.com/content/4/1/67
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in AGMs were next evaluated and compared to that of
rHPIV1 wt and the other two single att mutants (Table 3,
Groups 1, 3, 4, 5, 7, 8, and 9). The rHPIV1-CR84G/
Δ170HNT553ALY942A virus was strongly attenuated compared
to rHPIV1 mutants bearing the corresponding single att
mutations only in C/P, C/P/HN or L. The mean peak titer
of rHPIV1-CR84G/Δ170HNT553ALY942A in the URT and LRT
was reduced by 3.0 and 3.3 log10 TCID50/ml, respectively,
in comparison to HPIV1 wt (Table 3). Similarly, the addi-
tion of the HNT553A  and CΔ170  mutations to rHPIV1-
CR84GLΔ1710–11  to generate the rHPIV1-CR84G/
Δ170HNT553ALΔ1710–11 further attenuated the virus in AGMs,
restricting virus replication in comparison to HPIV1 wt by
3.1 and 3.4 log10 TCID50/ml in the URT and LRT, respec-
tively (Table 3). Therefore these two HPIV1 vaccine candi-
dates demonstrate strong attenuation phenotypes in vivo.
Considering the 9 viruses in Table 3 together, a relation-
ship was found to exist between level of temperature sen-
sitivity of replication in vitro and the attenuation
manifested in vivo, i.e., the lower the shut off tempera-
ture, the higher the level of in vivo attenuation (Figure 2).
Evaluation of these data using the Spearman rank test
gives correlation coefficients of 0.47 and 0.67 for the URT
and LRT, respectively, based on the mean daily sum of
virus titers for individual AGMs. This indicates a moderate
positive correlation with a stronger association between
the level of temperature sensitivity and virus replication in
the LRT. However, as might be expected, viruses bearing
only the non-ts attenuating P/C gene mutations, including
the CΔ170 and the CR84GHNT553A set of mutations, did not
follow this pattern (Figure 2), and we would expect a
higher correlation coefficient if these non-ts viruses were
not included in the analysis.
The levels of immunogenicity and protective efficacy
against HPIV1 wt challenge following immunization with
rHPIV1-CR84G/Δ170HNT553ALY942A  and rHPIV1-CR84G/
Δ170HNT553ALΔ1710–11 were also determined (Groups 8 and
9 in Table 4). The two vaccine candidates failed to induce
detectable HAI antibodies. However, immunization with
the rHPIV1-CR84G/Δ170HNT553ALY942A  was protective
against HPIV1 wt challenge in both the URT and LRT
(Table 4). In contrast, immunization with rHPIV1-CR84G/
Δ170HNT553ALΔ1710–11 did not offer significant protection
Table 4: Immunogenicity and protective efficacy of rHPIV1 vaccine candidates in AGMs.
Mean peak 
challenge virus titer 
(log10TCID50/ml) c
Mean sum of the 
daily challenge virus 
titers 
(log10TCID50/ml)d
Post-challenge 
serum HAI titerb
Virus a No. animals Pre-challenge 
serum HAI titerb
NP swab TL NP swab TL
1 HPIV1 wt 12 6.7 ± 0.6 (12/12) 0.8 ± 0.2f 0.7 ± 0.1 2.3 ± 0.2 2.4 ± 0.2 6.6 ± 0.5
2e rHPIV1-CR84G 4 3.8 ± 0.9 (3/4) ≤0.5 ± 0.0 ≤0.5 ± 0.0 ≤2.0 ± 0.0 ≤2.0 ± 0.0 4.4 ± 1.2
3e rHPIV1-CR84GHNT553A 12 6.0 ± 0.6 (11/12) 0.6 ± 0.1 0.6 ± 0.1 2.1 ± 0.1 2.1 ± 0.1 7.9 ± 0.4
4e rHPIV1-CΔ170 6 5.5 ± 0.4 (6/6) ≤0.5 ± 0.0 ≤0.5 ± 0.0 ≤2.0 ± 0.0 ≤2.0 ± 0.0 6.5 ± 0.4
5 rHPIV1-LY942A 4 6.3 ± 1.2 (4/4) 1.1 ± 0.2 1.2 ± 0.2 2.7 ± 0.3 2.8 ± 0.3 8.9 ± 1.1
6e rHPIV1-CR84GHNT553ALY942A 8 2.0 ± 0.0 (3/8) 0.8 ± 0.2 0.8 ± 0.2 2.6 ± 0.3 2.4 ± 0.3 3.3 ± 0.7
7 rHPIV1-CR84GLΔ1710–11 4 6.1 ± 1.8 (3/4) 3.4 ± 0.6 3.0 ± 0.6 8.4 ± 2.0 8.3 ± 1.3 6.9 ± 1.5
8 rHPIV1-CR84G/
Δ170HNT553ALY942A
4 ≤1.0 ± 0.0 (0/4) 2.2 ± 0.2 1.8 ± 0.5 5.1 ± 0.3 4.3 ± 1.3 5.5 ± 1.6
9 rHPIV1-CR84G/
Δ170HNT553ALΔ1710–11
4 ≤1.0 ± 0.0 (0/4) 4.5 ± 0.9 3.4 ± 0.4 11.8 ± 2.5 8.1 ± 1.3 7.5 ± 1.4
10 Non-immune 7 ≤1.0 ± 0.0 (0/4) 5.0 ± 0.6 3.9 ± 0.5 14.8 ± 1.2 11.0 ± 2.5 6.0 ± 1.3
a Monkeys were immunized i.n. and i.t. with 106 TCID50 of the indicated virus in a 1 ml inoculum at each site and were challenged on day 28 post-
infection with HPIV1 wt.
b HAI titers to HPIV1 were determined by HAI assay of sera collected at day 28 (pre-challenge) and day 56 (post-challenge) in separate assays. 
Titers are expressed as mean reciprocal log2± S.E.; the limit of detection was 1.0 ± 0.0. The number of animals with a 4-fold or greater increase in 
pre-challenge antibody titers is shown in brackets for each group.
c Mean ± S.E of the individual peak virus titers for the animals in each group irrespective of day. Virus titrations were performed on LLC-MK2 cells 
at 32°C. The limit of detection was 0.5 log10 TCID50/ml. NP and TL samples were collected on days 2, 4, 6 and 8 post-challenge.
d Mean sum of the daily virus titers: the sum of the titers for all of the days of sampling was determined for each animal individually, and the mean 
was calculated for each group. On days when no virus was detected, a value of was 0.5 log10 TCID50/ml was assigned for the purpose of calculation. 
The mean sum of the lower limit of detection was 2.0 log10 TCID50/ml for NP swabs and TL samples.
e These data have been previously published [13] [15] [16] and are included here for the purposes of comparison.
f Underlined values indicate statistically significant reductions in mean peaks or sum of daily virus titers for HPIV1 wt titer compared to the 
corresponding non-immune group, P < 0.05 (Student-Newman-Keuls multiple comparison test).Virology Journal 2007, 4:67 http://www.virologyj.com/content/4/1/67
Page 8 of 13
(page number not for citation purposes)
against HPIV1 wt challenge in the AGMs (Table 4), i.e., it
appeared overattenuated in this animal model. A relation-
ship was found between the level of replication of the
immunizing virus and its ability to induce resistance to
replication of the challenge virus (Tables 3 and 4), and
this is graphically displayed in Figure 3.
Discussion
The advent of a reverse genetics system for the generation
of infectious paramyxoviruses from full-length cDNA
plasmids has greatly facilitated the development of live
attenuated HPIV1 vaccine candidates [13-16]. The reverse
genetics system for HPIV1 has allowed site-directed
manipulation of the viral genome via cDNA intermedi-
ates, permitting the introduction of attenuating mutations
in desired combinations into vaccine candidates. It has
also been possible to genetically modify some of the
attenuating mutations to optimize genetic and pheno-
typic stability of viruses bearing the mutations, both by
the use of gene deletions and by using codons chosen for
a low probability of reversion. This process enables us to
optimize the safety profile of the live attenuated HPIV1
vaccine candidates before these viruses are tested in
humans.
We are focusing our efforts on the development of live
attenuated rHPIV1 vaccines since they have a number of
advantages over inactivated or subunit vaccines, including
the ability to: (i) induce the full spectrum of protective
immune responses including serum and local antibodies
as well as CD4+ and CD8+ T cells [11]; (ii) infect and rep-
licate in the presence of maternal antibody permitting
immunization of young infants [22,23]; (iii) cause an
acute, self-limited infection that is readily eliminated
from the respiratory tract; and (iv) replicate to high titers
in cell substrates acceptable for products for human use,
including qualified Vero cells, making manufacture of
these vaccines commercially feasible. In the present study,
two new rHPIV1 viruses containing single att mutations in
L, LΔ1710–11 and LY942A, were generated and characterized,
and these ts att mutations were used in combination with
previously described non-ts att mutations in the P/C gene
and HN gene to generate two new live attenuated HPIV1
vaccine candidates.
Representation of the relationship between the level of repli- cation of HPIV1 wt and rHPIV1 mutants in AGMs and the  subsequent level of replication of HPIV1 wt challenge virus in  the immunized animals Figure 3
Representation of the relationship between the level 
of replication of HPIV1 wt and rHPIV1 mutants in 
AGMs and the subsequent level of replication of 
HPIV1 wt challenge virus in the immunized animals. 
The mean peak virus titer (log10 TCID50/ml) in the URT fol-
lowing immunization (y-axis) was plotted for viruses 1–9 
(Table 3) against the mean peak challenge virus titers (log10 
TCID50/ml; x-axis) in the same groups (Table 4). A curve of 
best fit has been inserted (solid line) to demonstrate the 
association between these two data sets.
Representation of the association between the in vitro shut- off temperature and the attenuation phenotype in AGMs for  HPIV1 wt (W) and rHPIV1 mutant viruses Figure 2
Representation of the association between the in 
vitro shut-off temperature and the attenuation phe-
notype in AGMs for HPIV1 wt (W) and rHPIV1 
mutant viruses. For each virus (number designations cor-
respond to the virus group numbers assigned in tables 2-4), 
the shut-off temperature (°C), as determined by an in vitro 
temperature sensitivity assay (Table 2), was plotted against 
the mean sum of daily virus titers (log10 TCID50/ml; Table 3) 
in the URT (A) and LRT (B) of AGMs. rHPIV1 wt and non-ts 
rHPIV1 mutants were assigned a shut-off temperature of 
40°C for the purposes of this schematic. The limit of detec-
tion for the mean sum of daily virus titers is shown by a 
dashed line and viruses containing a single or set of non-ts 
attenuating mutation (**) or a single ts attenuating mutation 
(*) are highlighted, as shown. A linear trend line fit using the 
individual daily data is shown (solid line). The Spearman rank-
correlation coefficient was determined to be 0.47 for the 
URT and 0.67 for the LRT, indicating a moderate positive 
correlation between shut-off temperature and mean daily 
sum of virus titer in the URT and a stronger association for 
the LRT.Virology Journal 2007, 4:67 http://www.virologyj.com/content/4/1/67
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A major result of the present study was the creation of the
LΔ1710–11 mutation that was found to specify a strong ts att
phenotype. The LΔ1710–11 mutation was originally identi-
fied as an attenuating point mutation, LT1711I, in BPIV3
[19]. It was evaluated as a deletion mutation in the
present study since a deletion mutation offers a higher
level of genetic stability than a point mutation, a property
that is desirable for mutations in a vaccine candidate.
Indeed, since this deletion occurs in an ORF (in which the
triplet nature of the codons must be maintained) and in a
virus that conforms to the rule of six (in which the hex-
amer organization must be maintained), same-site rever-
sion would require the precise restoration of six
nucleotides. We unfortunately were not able isolate a
rHPIV1 mutant with only the LΔ1710–11 mutation since
each rHPIV1-LΔ1710–11 mutant that was isolated also pos-
sessed one or more adventitious mutations. The LΔ1710–11
mutation could only be recovered free of adventitious
mutations when it was in combination with the CR84G
mutation, and thus had to be studied in that context. We
acknowledge that it is possible that the phenotypes that
we observed for the rHPIV1-CR84GLΔ1710–11 are the result of
an interaction between the CR84G and LΔ1710–11 mutations.
However, we believe that this possibility is unlikely since
the CR84G mutation does not contribute to the ts or att phe-
notype of HPIV1 as an independent mutation. Further-
more, the high level of temperature sensitivity and
attenuation of rHPIV1-CR84GLΔ1710–11  versus that of
rHPIV1-CR84G suggests a major independent role of the
LΔ1710–11  mutation in these two phenotypes. rHPIV1-
CR84GLΔ1710–11 manifested a shut-off temperature of 37°C
in vitro and was restricted in replication in the URT and
LRT of AGMs by 2.5 log10 or 3.0 log10, respectively. There-
fore, we suggest that the LΔ1710–11 deletion mutation spec-
ifies a ts att phenotype for HPIV1, and, as such, it is a
suitable mutation to include in a HPIV1 vaccine candi-
date.
The LY942A mutation was identified previously as an atten-
uating mutation for introduction into potential HPIV1
vaccine candidates and was stabilized by codon optimiza-
tion studies [13]. These studies demonstrated that only
three amino acids were shown to specify a wild type phe-
notype at this codon position (the wild type tyrosine,
cysteine and phenylalanine) all of which would require
three nucleotide changes to convert the GCG alanine to a
codon specifying the wild type phenotype codon in the
vaccine virus [13]. In addition, the LY942A mutation was
shown to be highly stable under selective pressure during
passage at permissive and restrictive temperatures [13].
Previous studies have evaluated the LY942A mutation only
in the presence of the CR84GHNT553A set of mutations that
attenuates HPIV1 for AGMs [13,15]. To determine the
specific contribution of the LY942A mutation to the ts and
att  phenotypes associated with the rHPIV1-
CR84GHNT553ALY942A virus, a rHPIV1 containing only the
LY942A mutation was generated and was found to be as
attenuated as rHPIV1-CR84GHNT553ALY942A for AGMs. This
indicated that the LY942A mutation independently attenu-
ated HPIV1 for AGMs and can be used in the absence of
the CR84GHNT553A mutation to attenuate HPIV1 for AGMs.
The attenuation specified by the CR84GHNT553A mutation
was not additive with that of LY942A. This actually is a
desirable property, since it permits the inclusion of a
greater number of mutations while avoiding over-attenu-
ation, and these additional mutations would become
unmasked in the case of the loss of one or more other
mutations and would thus maintain the att phenotype.
Thus, LY942A is a stable mutation that specifies a ts att phe-
notype for HPIV1 and is suitable for introducing into a
HPIV1 vaccine candidate as an independent attenuating
mutation.
The LY942A and LΔ1710–11 ts att mutations were used in con-
junction with two of the non-ts att mutations, the
CR84GHNT553A and CΔ170 mutations [16], to develop two
live attenuated vaccine candidates for HPIV1, namely,
rHPIV1-CR84G/Δ170HNT553ALY942A  and rHPIV1-CR84G/
Δ170HNT553ALΔ1710–11. These vaccine candidates thus each
contain three independent attenuating mutations (two
non-ts att and one ts att mutation), two of which have
been genetically stabilized. The combination of muta-
tions present in these two vaccine candidates should
enhance the genetic and phenotypic stability of the
viruses, although this will require formal demonstration
in a clinical trial using clinical grade virus preparations.
Evaluation of the two vaccine candidates revealed that
they are reasonable candidates for further study in clinical
trials. Both candidates replicated well in Vero cells, a char-
acteristic that is important for manufacturing purposes.
Both viruses also demonstrated a strong ts phenotype in
vitro (shut-off temperature of ≤38°C) that was similar to
that of their ts parent virus, but the two viruses differ in
their level of temperature sensitivity in vitro. Since the
level of temperature sensitivity of respiratory viruses [24],
including HPIV1 as demonstrated here, correlates with
level of attenuation, it was anticipated that this difference
in the ts phenotype would be reflected in a difference in
the level of attenuation and immunogenicity in vivo, and
this indeed was seen. The HPIV1 vaccine candidates were
both strongly attenuated in the URT and LRT of AGMs,
with rHPIV1-CR84G/Δ170HNT553ALY942A  replicating to
slightly higher levels than the more ts  rHPIV1-CR84G/
Δ170HNT553ALΔ1710–11. Both vaccines were weakly immu-
nogenic and failed to induce a detectable level of serum
HAI antibodies in AGMs. A low level of protective efficacy
was observed in AGMs immunized with rHPIV1-CR84G/
Δ170HNT553ALY942A, but the rHPIV1-CR84G/
Δ170HNT553ALΔ1710–11 was not protective. This low level ofVirology Journal 2007, 4:67 http://www.virologyj.com/content/4/1/67
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immunogenicity and efficacy was not unexpected since
each vaccine was highly restricted in replication and since
there is a strong correlation between the level of replica-
tion of vaccine virus and its immunogenicity and ability
to restrict replication of HPIV1 challenge virus. These
results can be interpreted to indicate that the two vaccine
candidates are over-attenuated, but we think that this con-
clusion would be premature. It is likely that these viruses
will be more immunogenic, and therefore more effica-
cious, in humans compared to AGMs since they should
replicate more efficiently in humans. The reasons for this
are two-fold. First, HPIV1 is a human virus, and it should
replicate more efficiently in its natural host in which it
causes disease than in AGMs in which it causes only an
asymptomatic infection. The actual level of replication of
HPIV1 in seronegative humans is unknown, but it repli-
cates efficiently even in adults with pre-existing immunity
[25,26]. Second, these vaccine candidates are highly ts and
should replicate more efficiently in humans, which have a
lower body core temperature (36.7°C), than in AGMs
(approximately 39°C). Therefore, although these vaccine
candidates appear to be over-attenuated in AGMs, it is
expected that the viruses should replicate somewhat more
efficiently in humans and would be more immunogenic
than in AGMs. It also is fortunate that the two vaccine can-
didates appear to differ somewhat in their level of attenu-
ation, since this provides two chances to achieve an
optimal balance between safety and efficacy.
Conclusion
The rHPIV1-CR84G/Δ170HNT553ALY942A and rHPIV1-CR84G/
Δ170HNT553ALΔ1710–11 vaccine candidates are highly attenu-
ated in AGMs. We plan to initiate studies in humans with
the less attenuated vaccine candidate, rHPIV1-CR84G/
Δ170HNT553ALY942A. If this virus proves to be insufficiently
attenuated in the target population of young seronegative
infants (following an initial step-wise progression of
safety testing in adults, seropositive children, and seroneg-
ative children), we would proceed to evaluate the more
attenuated rHPIV1-CR84G/Δ170HNT553ALΔ1710–11  vaccine
candidate. If rHPIV1-CR84G/Δ170HNT553ALY942A  is over-
attenuated, then the LY942A mutation would be deleted
and the rHPIV1-CR84G/Δ170HNT553A  would be tested in
humans. In this way, we will identify a HPIV1 vaccine can-
didate that exhibits a satisfactory balance between attenu-
ation and immunogenicity for the target population of
seronegative infants and young children.
Methods
Cells and viruses
LLC-MK2 cells (ATCCCCL7.1) and HEp-2 cells
(ATCCCCL23) were maintained in Opti-MEM I (Gibco-
Invitrogen, Inc. Grand Island, NY) supplemented with 5%
FBS and gentamicin sulfate (50 μg/ml). Vero cells (ATCC
CCL-81) were maintained in Opti-PRO SFM (Gibco-Invit-
rogen, Inc.) in the absence of FBS and supplemented with
gentamicin sulfate (50 μg/ml) and L-glutamine (4 mM).
BHK-T7 cells, which constitutively express T7 RNA
polymerase [27], were kindly provided by Dr. Ulla Buch-
holz, NIAID, and were maintained in GMEM (Gibco-Inv-
itrogen, Inc.) supplemented with 10% FBS, geneticin (1
mg/ml), MEM amino acids, and L-glutamine (2 mM).
Biologically-derived wt HPIV1 Washington/20993/1964,
the parent for the recombinant virus system, was isolated
previously from a clinical sample in primary African green
monkey kidney (AGMK) cells and passaged 2 additional
times in primary AGMK cells [25] and once in LLC-MK2
cells [15]. This preparation has a wild type phenotype in
AGMs, and will be referred to here as HPIV1 wt. It was pre-
viously described as HPIV1LLC1  [15]. HPIV1 wt and
rHPIV1 mutants were grown in LLC-MK2 cells in the pres-
ence of 1.2% Tryple select, a recombinant trypsin (Gibco-
Invitrogen, Inc.), as described previously [8].
Construction of mutant HPIV1 cDNA
P/C, HN and L gene mutations (Table 1) were introduced
into the appropriate rHPIV1 subgenomic clones [14]
using the Advantage-HF PCR Kit (Clontech Laboratories,
Palo Alto, CA) with a modified PCR mutagenesis protocol
described elsewhere [28]. The entire PCR amplified subg-
enomic clone was sequenced using a Perkin-Elmer ABI
3100 sequencer with the Big Dye sequencing kit (Perkin-
Elmer Applied Biosystems, Warrington, UK) to confirm
that the subclone contained the introduced mutation and
to confirm the absence of adventitious mutations intro-
duced during PCR amplification. Full-length antigenomic
cDNA clones (FLCs) of HPIV1 containing the desired
mutations were assembled using standard molecular
cloning techniques [8], and the region containing the
introduced mutation in each FLC was sequenced as
described above to confirm the presence of the introduced
mutation and absence of adventitious changes. Each virus
was designed to conform to the rule of six, which is a
requirement by HPIV1 and numerous other paramyxovi-
ruses that the nucleotide length of their genome be an
even multiple of six for efficient replication [20].
Recovery of rHPIV1 mutant viruses
Three different recovery methods were used to generate
rHPIV1 mutants that differed in the source of the T7
polymerase needed to synthesize RNA from the trans-
fected virus-specific plasmids and, in one case, a different
transfection method was used. First, using previously
described procedures [8], rHPIV1 virus was recovered
from HEp-2 cells that were transfected with plasmids
encoding the antigenome and N, P, and L support pro-
teins and infected with an MVA-T7 vaccinia virus recom-
binant as a source of T7 polymerase. Second, Vero cells
were grown to 80% confluency and transfection experi-
ments were performed using the AMAXA Cell Line Nucle-Virology Journal 2007, 4:67 http://www.virologyj.com/content/4/1/67
Page 11 of 13
(page number not for citation purposes)
ofector Kit V, according to manufacturer's directions
(AMAXA, Koeln, Germany), as previously described [29].
Briefly, the cells were transfected with 5 μg each of the FLC
and the pCL-Neo-BCI-T7 plasmid (expressing T7
polymerase under the control of a eukaryotic promoter)
[30], 0.2 μg each of the N and P, and 0.1 μg of the L sup-
port plasmids. The transfection mixture was removed after
24 h at 37°C, and cells were washed and overlaid with
Opti-PRO with L-glutamine (4 mM) supplemented with
1.2% Tryple select. The cells and supernatant were trans-
ferred to LLC-MK2 cells in T25 cm2 flasks (Corning, NY) 7
days following transfection. Third, BHK-T7 cells constitu-
tively expressing T7 polymerase [27] were grown to 90 to
95% confluence in six-well plates. The cells were trans-
fected with 5 μg of the FLC, 0.8 μg each of the N and P,
and 0.1 μg of the L support plasmids in a volume of 100
μl of Opti-MEM per well. Transfection was carried out
with Lipofectamine 2000 (Invitrogen, Inc., Carlsbad, CA),
according to the manufacturer's directions. The transfec-
tion mixture was removed after a 24 h incubation period
at 37°C, and the cells were washed and maintained in
GMEM. On day 2 following transfection, the media was
supplemented with 1.2% trypsin, and the recovered virus
was harvested on days 2–4. All viruses were amplified by
passage on LLC-MK2 cells, and each was cloned by two
successive rounds of terminal dilution using LLC-MK2
monolayers in 96-well plates (Costar, Corning Inc.,
Acton, MA). To confirm that the recovered rHPIV1
mutants contained the appropriate mutations and lacked
adventitious mutations, viral RNA (vRNA) was isolated
from infected cell supernatants using the Qiaquick vRNA
kit (Qiagen Inc., Valencia, CA), reverse transcribed using
the SuperScript First-Strand Synthesis System (Invitrogen,
Inc., Carlsbad, CA) and amplified using the Advantage
cDNA PCR Kit (Clontech Laboratories). Each viral
genome was sequenced in its entirety.
Evaluation of recombinant HPIV1 vaccine candidates in a 
multiple cycle growth curve
The recombinant HPIV1 mutants were compared to
HPIV1 wt on LLC-MK2 and Vero cells at 32°C in a multi-
ple cycle growth curve. Confluent monolayer cultures in
6-well plates were infected in triplicate at a multiplicity of
infection (MOI) of 0.01 50%-tissue-culture-infectious-
doses (TCID50) per cell in media containing trypsin. The
residual inoculum was withdrawn 2 h post infection as
the day 0 sample and was replaced by medium with
trypsin. On days 2, and 4–11 post-infection, the total
medium supernatant was removed for virus quantitation
and was replaced with fresh medium with trypsin. Super-
natants containing virus were frozen at -70°C, and all
samples were tested together for virus titer with endpoints
identified by hemadsorption.
Characterization of the temperature sensitivity of the 
rHPIV1 vaccine candidates
The ts phenotype for each mutant rHPIV1 virus was deter-
mined by comparing its level of replication to that of
HPIV1 wt at 32°C and at 1°C increments from 35°C to
40°C, as described previously [31]. Briefly, each virus was
serially diluted 10-fold in 96-well LLC-MK2 monolayer
cultures in L-15 media (Gibco-Invitrogen, Inc.) contain-
ing trypsin with four replicate wells per plate. Replicate
plates were incubated at the temperatures indicated above
for seven days, and virus infected wells were detected by
hemadsorption with guinea pig erythrocytes. The virus
titer at each temperature was determined in three to six-
teen separate experiments and is expressed as the mean
log10 TCID50/ml. The mean titer at an elevated tempera-
ture was compared to the mean titer at 32°C, and the
reduction in mean titer was determined. The shut-off tem-
perature of an rHPIV1 mutant is defined as the lowest
temperature at which the reduction in virus titer com-
pared to its titer at 32°C was 100-fold greater than the
reduction in HPIV1 wt titer between the same two temper-
atures. A mutant is defined as having a ts phenotype if its
shut-off temperature is ≤40°C.
Evaluation of replication of viruses in AGMs and efficacy 
against challenge
AGMs in groups of two to four animals at a time were
inoculated intranasally (i.n.) and intratracheally (i.t.)
with 106 TCID50 of either HPIV1 wt or mutant rHPIV1 in
a 1 ml inoculum at each site. NP swab samples were col-
lected daily from days 1 to 10 post-inoculation, and TL
fluid samples were collected on days 2, 4, 6, 8 and 10 post-
inoculation. The specimens were flash frozen and stored
at -80°C and were subsequently assayed in parallel. Virus
present in the samples was titered in dilutions on LLC-
MK2 cell monolayers in 96-well plates and an undiluted
100 μl aliquot was also tested in 24-well plates. These
were incubated at 32°C for 7 days. Virus was detected by
hemadsorption, and the mean log10 TCID50/ml was calcu-
lated for each sample day. The limit of detection was 0.5
log10TCID50/ml. The mean peak titer for each group was
calculated using the peak titer for each animal, irrespective
of the day of sampling. The mean sum of the virus titers
for each group was calculated from the sum, calculated for
each animal individually, of the virus titers on each day of
sampling, up to day 10. The sum of the lower limit of
detectability was 5.0 log10 TCID50/ml for NP swabs and
2.5 log10 TCID50/ml for TL samples.
On day 28 post-inoculation, the AGMs were challenged
i.n. and i.t. with 106 TCID50 of HPIV1 wt in 1 ml at each
site. NP swab and TL samples were collected for virus
quantitation on days 2, 4, 6 and 8 post-challenge.Virology Journal 2007, 4:67 http://www.virologyj.com/content/4/1/67
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All animal studies were performed under protocol LID22,
as approved by the National Institute of Allergy and Infec-
tious Disease (NIAID) Animal Care and Use Committee
(ACUC).
Evaluation of immune responses in AGMs
Serum was collected from each monkey on days 0 and 28
post-immunization and on day 28 post-challenge (day 56
post-immunization). HPIV1 HAI antibody titers were
determined at 21°C, as described previously [32], using
0.5% v/v guinea pig erythrocytes and HPIV1 wt as the
antigen. The HAI antibody titer was defined as the end-
point serum dilution that inhibited hemagglutination
and is expressed as the mean reciprocal log2 ± standard
error (SE).
Statistical Analysis
The Prism 4 (GraphPad Software Inc., San Diego, CA)
one-way ANOVA test, (Student-Newman-Keuls multiple
comparison test) was used to assess statistically significant
differences between data groups (P < 0.05). The R soft-
ware programme [33] was used to perform a Spearman
rank test to determine correlation between data sets.
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